Rising to the challenges of rare disease treatment
Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Specialized BioTherapeutics Pipeline
Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.
| Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review | Market |
|---|---|---|---|---|---|
| HyBryte™ Cutaneous T-Cell Lymphoma (CTCL) Treatment | |||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
NDA Review
|
Market
|
| SGX302 Plaque Psoriasis Treatment for Mild to Moderate Psoriasis | |||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
NDA Review
|
Market
|
| SGX942 for Oral Mucositis Treatment | |||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
NDA Review
|
Market
|
| SGX945 for Aphthous Ulcers of Behçet’s Disease | |||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
NDA Review
|
Market
|
| SGX203 for Pediatric Crohn’s Disease | |||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
NDA Review
|
Market
|
Orphan and/or Fast Track Designation
Denotes funding by NIH, BARDA, DTRA and/or FDA.
Public Health Solutions Pipeline
Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.
| Proof-of-Concept | IND | Phase 1 | Phase 2/3 | BLA Review | Market |
|---|---|---|---|---|---|
| RiVax® to Prevent Ricin Poisoning | |||||
|
Proof-of-Concept
|
IND
|
Phase 1
|
Phase 2/3
|
BLA Review
|
Market
|
| SGX943 for Bacterial Infection Treatment | |||||
|
Proof-of-Concept
|
IND
|
Phase 1
|
Phase 2/3
|
BLA Review
|
Market
|
| ThermoVax® Thermostable Vaccines for Global Use | |||||
|
Proof-of-Concept
|
IND
|
Phase 1
|
Phase 2/3
|
BLA Review
|
Market
|
Orphan and/or Fast Track Designation
Denotes funding by NIH, BARDA, DTRA and/or FDA.
The Latest
Resources
News
External Link
“Visible Light Activated Topical Hypericin Ointment in CTCL: Phase 3 FLASH Study Results” presented by Ellen Kim, MD at the American Academy of Dermatology Virtual Meeting Experience April 24, 2021 (AAD 2021)
“Visible Light Activated Topical Hypericin Ointment in CTCL: Phase 3 FLASH Study Results” presented by Ellen Kim, MD at the American Academy of Dermatology Virtual Meeting Experience April 24, 2021 (AAD 2021)
External Link
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…